ARK Genomic Revolution ETF (BATS:ARKG) Shares Acquired by Atom Investors LP

Atom Investors LP lifted its position in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 15.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 49,131 shares of the company’s stock after purchasing an additional 6,496 shares during the period. Atom Investors LP’s holdings in ARK Genomic Revolution ETF were worth $1,258,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Cetera Investment Advisers boosted its position in ARK Genomic Revolution ETF by 290.7% during the first quarter. Cetera Investment Advisers now owns 140,897 shares of the company’s stock worth $4,052,000 after purchasing an additional 104,831 shares in the last quarter. PFM Health Sciences LP acquired a new stake in ARK Genomic Revolution ETF in the 3rd quarter valued at $2,226,000. Main Management ETF Advisors LLC grew its stake in ARK Genomic Revolution ETF by 2.3% in the 2nd quarter. Main Management ETF Advisors LLC now owns 2,754,610 shares of the company’s stock valued at $64,678,000 after acquiring an additional 62,470 shares during the period. Mercer Global Advisors Inc. ADV raised its position in ARK Genomic Revolution ETF by 901.5% during the second quarter. Mercer Global Advisors Inc. ADV now owns 28,943 shares of the company’s stock worth $680,000 after acquiring an additional 26,053 shares during the period. Finally, Headlands Technologies LLC lifted its holdings in ARK Genomic Revolution ETF by 5,878.2% during the second quarter. Headlands Technologies LLC now owns 21,163 shares of the company’s stock valued at $497,000 after purchasing an additional 20,809 shares in the last quarter.

ARK Genomic Revolution ETF Price Performance

ARKG stock opened at $25.70 on Wednesday. The stock’s 50 day moving average is $24.62 and its 200-day moving average is $25.10.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.